Mannkind (MNKD) Asset Writedowns and Impairment (2017 - 2026)
Mannkind (MNKD) reported Asset Writedowns and Impairment of $1.1 million for Q1 2026, up 130.69% year-over-year from $466000.0 in Q1 2025, and down 48.74% quarter-over-quarter from $2.1 million in Q4 2025.
Mannkind (MNKD) Asset Writedowns and Impairment (2017 - 2026) Analysis & Trends
Mannkind (MNKD) has 9 years of Asset Writedowns and Impairment data on file, last reported at $1.1 million in Q1 2026.
- Asset Writedowns and Impairment for Q1 2026 came in at $1.1 million, up 130.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.1 million (up 234.3% YoY), and the FY2025 annual result was $10.4 million, up 169.7% from the prior year.
- Asset Writedowns and Impairment retreated to $1.1 million in Q1 2026 per MNKD's latest filing, from $2.1 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $4.6 million in Q2 2025 and troughed at $300000.0 in Q3 2023.
- A 5-year average of $1.4 million and a median of $950000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2023 and 2025: Asset Writedowns and Impairment sank 66.67% in 2023, then soared 1000.0% in 2025.
- A 5-year view of Asset Writedowns and Impairment shows it stood at $834000.0 in 2022, then increased by 4.8% to $874000.0 in 2023, then soared by 122.65% to $1.9 million in 2024, then increased by 7.76% to $2.1 million in 2025, then slumped by 48.74% to $1.1 million in 2026.
- Business Quant data shows MNKD's Asset Writedowns and Impairment at $1.1 million in Q1 2026, $2.1 million in Q4 2025, and $3.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Mar 31, 2025 | 466,000.00 |
| Mar 31, 2025 | 466,000.00 |
| Dec 31, 2024 | 1.95 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 874,000.00 |
| Dec 31, 2023 | 874,000.00 |